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A possible role for nitric oxide in modulating the functional cyclosporine
toxicity by arginine. The renal damage consequent to cyclosporine A
(CsA) administration ranges from hemodynamic alterations to irreversible
chronic lesions. The initial vasoconstriction depends upon the imbalance
between the various modulators of the renal vascular tone, among which
the most powerful are endothelins and nitric oxide (NO). CsA could play
a crucial role by inhibiting the Ca/calmodulin-mediated activation of
the constitutive NO synthase (NOS) isoform, which converts L-arginine
(L-Arg) into NO and citrulline, with a 1:1 stoichiometry. To investigate the
possibility of modulating CsA nephrotoxicity with L-Arg we studied six
groups (G) of Lewis rats treated with daily gavage up to eight weeks: Gi,
CsA 40 mg/kg; G2, Gi plus L-Arg 300 mg/kg; G3, G2 plus the competitive
inhibitor of NOS, N'-nitro-L-Arg (L-NNA); G4, L-Arg alone; G5,
L-NNA alone; and G6, controls receiving vehicle alone. After eight weeks
L-Arg treated rats were protected against the toxic effects of CsA
[creatinine (Cr) values, G2, 0.62 0.05 mg/dl vs. Gi, 0.99 0.16 mg/dl,P < 0.001; proteinuria (P), G2, 7.2 1.02 mg/day vs. Gi, 15.1 1.9
mg/day, P < 0.01]. The administration of L-NNA abolished the protective
effect of L-Arg (G3, Cr 1.23 0.16 mg/dl; P 16.9 = 2.3;P < 0.02 and P <
0.005, respectively vs. G2). The levels of Cr in G2 rats were superimpos-
able to control groups. The NOS activity, evaluated by measuring
[3Hlcitrulline formation from [3H]L-Arg in kidney homogenates, was
blocked by L-NNA in G5 (0.019 0.009 pmol/min/mg proteins vs. G6
0.047 0.002, P < 0.01). NOS activity was significantly increased versus
controls in Gi (0.110 0.032, P < 0.01) and G2 (0.088 0.009, P < 0.02),
while L-NNA reversed this phenomenon (G3, 0.052 0.03). The expres-
sion of mRNA encoding for cNOS and iNOS was only slightly increased
in CsA-treated rats. We suggest that CsA treatment increases NOS activity
in the kidney by a mechanism which does not require a de novo synthesis
of the enzyme. Such an increase, that may be devoted to counterbalance
the vasoconstrictive effects of the drug, is unable to reduce the toxic effect
of CsA in the absence of exogenous L-Arg. Administration of L-Arg is
likely to reduce CsA nephrotoxicity by accomplishing the higher request of
activated NOS for its substrate, thus potentiating NO synthesis in the
kidney.'
The full potential employment of cyclosporine A (CsA) in the
prevention of rejection in organ transplantation [1, 2] and in many
other therapeutical applications [3] is limited by the occurrence of
several important side effects, particularly nephrotoxicity [3, 4].
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Renal disfunction can occur at any time and ranges from an
early reversible functional damage to a late progression to irre-
versible chronic renal failure. Acute nephrotoxicity may appear
soon after transplantation or after weeks or months, with oliguria,
acute decrement of glomerular filtration rate and renal plasma
flow [3—7]. Due to the lack of histological lesions, the acute
toxicity is usually believed to be consequent to renal vasoconstric-
tion [3—7]. Conversely, after prolonged CsA administration
chronic nephrotoxicity is characterized by a progressive and
mostly irreversible impairment of renal function, and it is sup-
ported by histological lesions ranging from striped fibrosis to
ischemic collapse of the tuft, glomerular sclerosis and tubular
atrophy [8]; however, the increase in interstitial matrix preceding
the interstitial fibrosis might be due to a direct toxic effect of CsA
[4,6].
Several factors contribute to CsA-induced vasoconstriction,
including adrenergic mediators and renin-angiotensin axis hyper-
stimulation [9—11]. Moreover, the capacity of CsA to be inserted
into the lipid bilayer of the cell membrane and activate phospho-
lipase A2 has suggested a possible interference of this drug in the
arachidonic acid metabolism [12—14]. A pivotal role in CsA
toxicity seems to be played by endothelins (ET) [15, 16], as the
synthesis of both ET and vasoconstrictive eicosanoids implicates
an increase in cytosolic Ca . Several attempts to modulate CsA
nephrotoxicity through the employment of Ca antagonists have
been proposed [5, 17, 18].
Experimental evidence suggests an important role of the de-
crease of vasorelaxant mediators in the pathogenesis of the renal
vasoconstrition initiating CsA nephrotoxicity [19—21]. Among
these substances, the endothelium-derived relaxing factor (EDRF),
now biochemically characterized as nitric oxide (NO), is one of
the most effective [22, 23]. Endothelium-derived NO has been
demonstrated to play an important role in the local regulation of
blood flow in kidney and in other organs [22]. It is produced in
many tissues by a family of NO synthases (NOS), which transform
L-arginine (L-Arg) into NO and L-citrulline, with a 1:1 stoichi-
ometry [22, 24, 25]. A constitutive Ca /calmodulin-dependent
form (cNOS) is activated by agonists that increase intracellular
Ca + and is blocked by the binding of CsA to calmodulin via the
formation of the complex CsA!cyclophilin [5, 23, 24]. Another
NOS isoform is Ca k-independent and inducible by endotoxin
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and many cytokines (iNOS) [22]. Recently a Ca -dependent,
calmodulin-independent NOS has been described [22]. NO, by
stimulating the cytosolic guanylate cyclase, is able to induce an
increase of cyclic GMP (cGMP) production [26] which can
account for the vasodilating effect of NO. An NO-mediated
increase of cGMP has been observed not only in smooth muscle
cells but also in other contractile cells, such as endothelium,
pericytes and mesangial cells [27, 28]. It has been demonstrated
that CsA chronic administration impairs NO production by rat
kidney arteries [19, 20].
At the time of the first description of renal vasoconstriction
induced by CsA, the role of nitric oxide had not been character-
ized. Therefore we aimed this study to: (1) investigate the effects
of in vivo administration of CsA on the NOS activity in the rat
kidney; (2) evaluate the possibility of modulating CsA nephrotox-
icity by administrating L-Arg to increase the substrate availibility
for NO synthesis and then to counteract the renal vasoconstric-
tion.
Methods
Experimental design
Experiments were conducted in 90 male Lewis rats (150 to 170
g body weight) (Charles River, Calco, Italy). Animals were allowed
free access to tap water and each had 16 glday of standard rat
laboratory diet.
Six groups of rats were identified.
The first group (Gi) received CsA (Sandoz Pharmaceutical,
Morris Plains, USA) by daily intragastric gavage at the dose of 40
mg/kg, using as vehicle a 10% fat emulsion (Intralipid, Kabivit-
rum, Stockholm, Sweden). G2 received CsA plus L-Arg 300 mg/kg
by the same intragastric route. G3, together with CsA and L-Arg
also received NGnitroLarginine (L-NNA), a competitive antag-
onist of L-Arg, 5 mg/kg.
G4 to G6 were the pair-fed control groups: G4 rats were treated
with L-Arg alone, G5 with L-NNA alone and G6 with the
lipophilic vehicle alone.
In every group eight animals were sacrificed at the fourth week
and the remaining seven at the eighth week. At the end of the
experiment, before sacrifice, 24-hour urine collections from rats in
individual metabolic cages and blood samplings were performed.
One kidney was used for morphologic studies and the other was
snap frozen and stored at —70°C until the check of NOS activity
and RNA extraction. Data from three separate experiments, each
including all six groups of rats, were pooled because the results
were superimposable.
Five rats in group Gi, four rats in G2 and four controls (G6)
underwent a measurement of radioisotopic glomerular filtration
rate (GFR) and effective renal plasma flow (ERPF) before
sacrifice at four weeks.
Blood and urine analysis
CsA blood levels. CsA in whole blood was assayed 24 hours after
the last administration by means df a RIA kit employing a
monoclonal antibody (CycloTracR, Incstar Corporation, Stiliwa-
ter, MN, USA).
Plasma creatinine levels. After centrifugation of blood samples
collected in EDTA 0.2 M, serum creatinine was determined using
the Jaffé's colorimetric method on a Cobas-Miras Instrument
(Roche Diagnostic System, Milan, Italy).
Proteinuria. After the 24 hour collection, urines were centri-
fuged to eliminate cells and the dosage was performed on the
supernatant by evaluating the turbidity induced by 3% sulfosali-
cilic acid and 7% sodium sulfate in distilled water, The protein
concentration was expressed in mg/24 hr with human albumin as
standard.
Urinary excretion of cGMP. Urinary cGMP was evaluated using
a commercial RIA kit (UVWR, Prague, Czechoslovakia).
Measurement of NOS activity on renal tissue homogenates
Renal tissues from each experimental animal were frozen in 1
ml of reaction buffer (mM: Hepes 20, EDTA 0.5, dithiothreitol 1,
pH 7.2), homogenated and then sonicated on ice with three
10-second bursts. In each test tube, the following reagents were
added to 100 l homogenate at the final concentrations: 2 mM
NAPDH, 1.5 mivi CaCl2, 1 to 100 tM L-arginine, 2.5 Ci (=0.4
!.LM) L-[2, 3, 4, 5-3H]arginine monohydrochioride (62 Ci/mmol;
Amersham International, Bucks, UK) [29, 30]. After a 30 minute
incubation at 37°C, the reaction was stopped by adding 2 ml of 20
mM Hepes-Na pH 6 containing 2 mM EDTA. The whole reaction
mixture was applied to 2 ml columns of Dowex AG5OWX-8 (Nat
form; Aldrich, Milano, Italy) and eluted with 4 ml of water. At pH
6 arginine is negatively charged, while citrulline is neutral: the
Dowex resin is a cationic exchanger which biiids arginine but not
citrulline in these conditions. The radioactivity corresponding to
[3H]citrulline content in 6 ml eluate was measured by liquid
scintillation counting. NOS activity was expressed as pmol citrul-
line/mm/mg protein. The protein content of homogenates was
assessed with the modified micro-Lowry method (Kit from Sigma,
St. Louis, MO, USA).
mRNA analysis of inducible (iNOS) and constitutive (cNOS)
forms of the enzyme in renal tissues
Renal tissue from three animals of each esperimental group was
processed for molecular biology studies. Total RNA was obtained
by the guanidine isothiocyanate/cesium chloride method [31].
Twenty-five micrograms of total RNA were electrophoresed on a
1% agarose gel containing 6.3% formaldehyde in 4-morpho-
linepropanesulfonic acid (MOPS, Sigma) buffer and blotted on a
Nylon Duralon-UV membrane (Stratagene, La Jolla, CA, USA)
by the traditional capillary system in 10 X SSC [32]. Pre-
hybridization and hybridization steps were performed overnight in
50% deionized formamide, 10% dextran sulfate, 1 M NaC!, with
100 mglml denaturated salmon sperm DNA at 42°C. The cDNA
for endothelial, constitutive cNOS [33] (a gift from Dr. T Michel,
Brigham and Women's Hospital, Boston, MA, USA) and iNOS
[34] (a gift from Dr. C. Nathan, Cornell University of Medical
College, New York, NY, USA) were labeled with [a32-P]dCTP
(3000 Ci/mmol, Amersham) at 2.2 X 108 cpm/mg specific activity,
by the random primer labeling kit (Arnersham) according to the
manufacturer's instructions. Post-hybridization washes were per-
formed at high stringency (twice in 2x SSC + 0.1% SDS for 30
mm at room temperature, twice in 0.2x SSC + 0.1% SDS for 30
mm at room temperature, and twice in 0.lx SSC + 0.1% SDS for
30 mill at 55°C), and the membrane was exposed on autoradiog-
raphy with Hyperfilm-MP (Amersham) and intensifying screen at
—80°C for 20 days. RNA loading and transfer to membranes was
checked by examination under UV light. The optical density of
the autoradiography bands integrated for the band area was
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evaluated by a digitized image analyzer (RAS 3000, Coat System,
Amersham).
Radioisotopic measurement of GFR and ERPF
The measurements were performed on conscious rats to avoid
the hemodynamic modifications induced by anesthetics. The
experimental method described by Tauxe [35] was employed with
modifications, using [51Cr] EDTA (Amersham) and o-1251-hippu-
ran (Sorin, Italy) as tracers. A total of 0.2 1tCi/100 g body wt of
[51Cr] EDTA and 0.4 tCi/100 g body wt of o-'251-hippuran were
injected in the caudal vein and blood sampling was performed 30,
60 and 90 minutes after the injection. The blood samples were
centrifuged at 3,000 rpm for 10 minutes and the sera counted for
10 minutes in a Packard Autogamma 5130 gamma counter.
GFR was calculated according to the following formula to
evaluate the distribution volume:
standard counts(cpm) X (weight dose)(g)/(weight standardXg)
and from this value:
X 1000 divided by intercepts on T0
GFR (mI/miss) = distribution volume x 0.65 X 1000 divided by T1/2
Effective renal plasma flow was calculated using the following
formula [35]:
ERPF (mi/miss) = 1126.2 x [1 — C — 0.008 (v30 — 7.8)
where v30 represents the theoretical distribution volume 30
minutes after the injection.
Renal tissue morphology studies
Longitudinal sections of kidneys were fixed in Serra fluid for 24
hours at room temperature, dehydrated with ethanol and xylene
and embedded in paraffin. Section at 4 im thickness were stained
with hematoxylin eosin, periodic acid Schiff reagent and Masson
trichrome.
Statistical analysis
The statistical analyses were performed using the Statview512
software (Brainpower, Calabasas, CA, USA) on a Macintosh
Personal Computer (Cupertino, CA, USA). Data are given as
mean values SD. The different groups were compared using
analysis of variance (ANOVA test) and statistical significance was
defined as P < 0.05.
Results
CsA blood levels
Mean blood levels of CsA were very high in the treated groups
(Gi, G2, G3), confirming a good enteric absorption of the drug
(Gi 6840 842 ng/ml, G2 8053 745, G3 8128 793 ng/ml). No
significant difference was observed among these groups.
Serum creatinine and urinary protein losses
After four weeks and even more after eight weeks of daily
treatment with CsA, G1 rats displayed serum creatinine levels
significantly higher than controls (G6) (P < 0.02 at 4 weeks, P <
0.001 at 8 weeks; Fig. 1). In this group creatinine values were
Fig. 1. Serum creatinine levels (mg/mi) in Gi to G6 rats at 4 weeks and
8 weeks . For the statistical significance see the text.
twofold higher after four weeks and threefold higher after eight
weeks than in rats treated with the vehicle alone [Go].
In comparison to the rats receiving CsA alone (Gi), the rats
treated with both CsA and L-Arg (G2) showed significantly lower
creatinine levels at four (P < 0.05) and eight weeks (P < 0.01). In
comparison to Gi, G2 rats also displayed lower urinary protein
loss at four (P < 0.05) and eight weeks (P < 0.01). The protective
effect induced by L-Arg appeared particularly evident after four
weeks of treatment, when serum creatinine and urinary protein
excretion values were only slightly and not significantly higher
than in rats treated with L-Arg alone (G4). After eight weeks of
treatment the protective effect induced by L-Arg on CsA func-
tional nephrotoxicity was still present, even though less strong,
and creatinine levels and proteinuria in G2 were significantly
higher than in G4 (creatinine P < 0.05; proteinuria P < 0.02).
Moreover, in these G2 rats a significant increase in serum
creatinine values (P < 0.01) and urinary protein excretion (P <
0.02) was evident from the fourth to the eighth week, indicating a
progression of CsA-induced nephrotoxicity.
After four weeks of treatment serum creatinine levels in G3
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were significantly higher than in G2 (P < 0.005) and Gi (P <
0.02). At the eighth week of treatment serum creatinine levels in
G3 were still higher than in Gi (P < 0.05) and G2 (P < 0.02).
After four weeks, urinary protein excretion values in G3 were not
significantly different than in the groups receiving CsA (Gi and
G2), but at the eighth week the values were significantly higher
than in the rats given CsA and L-Arg (G2) (P < 0.005). These
data suggest that the protective effect exerted by L-Arg was
mediated via its conversion to NO.
Moreover in G3 rats a progressive impairment of renal function
from the fourth to the eighth week was observed (P < 0.05) and
urinary protein excretion values increased significantly during this
time (P < 0.02).
Urinary cGMP excretions
A slight increase of urinary cGMP excretion was observed in
CsA-treated groups (GI, G2, G3) (Fig. 2) in comparison to the
control groups (G4, G5, G6) without any significant difference
between the groups.
NOS activity in renal tissue homogenates
NOS activity was high in the group treated with CsA alone (G1
vs. G6, P < 0.01). The increase of enzyme activity was completely
abolished in animals receiving both the inhibitor and CsA (G3). In
vitro renal NOS activity was increased in rats receiving L-Arg only
if they were simultaneously given CsA (G2 vs. G4, P < 0.02).
Administration of L-NNA, a competitive inhibitor of both cNOS
and iNOS, induced a stable blockage of NOS activity in renal
tissue from G5 rats (Fig. 3).
mRNA encoding for iNOS and cNOS in renal tissue
To investigate the mechanism leading to increased NOS activity
in rats treated with CsA, the expression of iNOS and cNOS
transcripts was studied. Figure 4 shows representative Northern
blots whereas Figure 5 summarizes the results as arbitrary densi-
tometry units,
G2 and G3, independently from the administration of L-Arg or
L-NNA contemporary to CsA, had some increase in cNOS and to
a lesser extent iNOS mRNA expression (Fig. 4). The amounts of
both iNOS and cNOS transcripts were not significantly different
among the various groups (Fig. 5).
After four weeks of CsA treatment in comparison to the control
rats (G6) Gi rats displayed a clear-cut decrease of GFR values
(P < 0.02) and of ERPF (P < 0.01) (Fig. 6). The filtration fraction
(FF) resulted significantly increased (P < 0.05).
L-Arg treatment in association to CsA in G2 rats was able to
limit CsA hemodynamic effects: GFR and ERPF in G2 were
significantly greater than in Gi (P < 0.05) while FF was signifi-
cantly lower (P < 0.05). Interestingly, GFR, ERPF and FF values
in G2 were similar to control G6 (P = NS).
Renal morphology
Light microscopy did not show evidence of lesions either at the
fourth or eighth week. In particular vascular and tubular changes
as well as striped interstitial fibrosis were not observed.
Discussion
The daily CsA dose administered in our model (40 mg/kg/day),
although similar to other protocols reported in the literature [6],
is much higher than that employed in human kidney transplanta-
tion. High CsA blood levels are necessary to overcome the natural
resistance of the rat to the renal toxic effects of this drug [36] and
to exert a maximal effect. A simple transposition of a dose-effect
relationship from rats to humans is therefore impossible. The
L-Arg doses given per os were high as well (300 mg/kg) and
analogous doses administered i.v. were able to worsen hypothen-
sion until death in endotoxin shock models [37]. L-NNA at the
employed dose of 5 mg/kg is able to block the enzymatic activity
of both iNOS and cNOS, the last able to be inhibited by even
lower amounts [37].
The administration of CsA over four weeks was planned to
investigate an initial chronic effect of the drug, since acute toxicity
is usually evaluated after seven days [6, 38]. The lack of histolog-
ical lesions at four weeks in the subset of animals sacrificed in
each group prompted us to continue the experiments until eight
weeks, but not longer, since a pivotal study previously showed that
at 10 weeks the rats treated with CsA plus L-Arg and L-NNA
showed an initial sickness with weight loss until death. At that
time, however, no histological signs of nephrotoxicity were detect-
able as well, according to the reports that interstitial fibrosis
develops only after four months [8]. We did not carry out low
sodium diet [39] or mononephrectomy [40], which would have
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Fig. 4. Expression of iNOS and cNOS mRNA in rat kidneys. Total RNA
(25 jg for each lane) extracted from kidneys of animals belonging to
different experimental groups was examined by Northern blot analysis.
Comparable amounts of total RNA were transferred to filters as shown by
ethidium bromide staining (bottom of the figure). Integrity of RNA was
evidenced by the clear bands.
enhanced the development of histological signs of nephrotoxicity,
in order to avoid an additional increase of angiotensin II activity.
After four weeks of daily CsA administration we observed a
significant increase of serum creatinine levels, which worsened
after eight weeks and was inhibited by L-Arg and reversed by
L-NNA, a well known NOS inhibitor.
These data, in absence of histological lesions, are consistent
with a vasocostrictive effect of the drug. Several observations
indicate that CsA induces an uncompensated preglomerular
vasoconstriction [7, 41]. CsA interferes with the normal endothe-
hum-dependent relaxation of the afferent arteriole [19] and with
the compensatory generation of angiotensin II in the kidney [42].
In an acute CsA toxicity model an afferent arteriolar vasoconstric-
tion was demonstrated, which was reversed by L-Arg [38].
The glomerular hemodynamic investigations performed in this
C
>..
study by radioisotopic GFR and ERPF measurement confirmed
the hypothesis that the major protective effect of L-Arg on CsA
toxicity was mediated by opposing its hemodynamic modifications.
After CsA administration at fourth week there was a 50%
decrease of GFR and a 30% decrease of ERPF; these data were
in agreement with the results obtained by other authors employ-
ing inulin and paraaminohippuric acid clearance [43]. We found a
clear filtration fraction increase in CsA-treated animals; this is
considered to be an index of glomerular hyperfiltration, and
actually we observed a parallel 10-fold increase in urinary protein
excretion. It is noteworthy that the group treated with both CsA
and L-Arg showed a clear reduction of filtration fraction until
normalization, and a significant protection against the develop-
ment of proteinuria.
Taken as a whole, these data support the hypothesis that the
severe glomerular hemodynamic alteration induced by CsA leads
to glomerular hyperfiltration and permselectivity alterations
which are counterbalanced by the administration of L-Arg, the
physiological substrate of NOS.
However, since the hemodynamic indices were not completely
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Fig. 5. mRNA encoding for cNOS and iNOS. Results are expressed in
arbitrary units after densitometry measure.
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Fig. 6. Renal hemodynamics in Cl rats treated with CsA alone, G2 (CsA +
L-A,g) and G6 control group. For the statistical significance see the text.
reversed by L-Arg, and a small increase in creatinine and protein-
uria—already evident at the 4th week—became significant at
eighth week, there admittedly are additional CsA effects on
pressures and flow across the glomerular capillary wall unaffected
by L-Arg administration.
To investigate whether the protective effects of L-Arg on CsA
nephrotoxicity were mediated by NO-elicited guanylate cyclase
activation we measured urinary cGMP. The rats treated with CsA
showed a slight but not significant increase in urinary cGMP
excretion in comparison to controls, and there were no differences
between the three groups given CsA. Such a result could be
accounted for by the very low levels of cGMP detectable in urine
and by the fact that cGMP urinary excretion could derive from the
action of other mediators, such as PGE2 or atrial natriuretic
factor. Moreover, cGMP is an unstable compound [22, 26] that
can quickly lose its antigenic properties, becoming unrecognized
by the antibody employed in the immunoenzyme assay adopted.
A more direct approach is to measure NOS activity in renal
tissue homogenates. This technique, which permits evaluation of
the in vitro NOS activity in the presence of large excess of
substrate, quantifies citrulline, which is produced equimolarly with
NO from L-Arg. NOS activity in the kidney was blocked in the rats
treated with L-NNA, an inhibitor of both inducible and constitu-
tive forms of NOS. Our data suggest that renal NOS is inhibited
by L-NNA. In fact, in vivo administration of the inhibitor caused
a permanent decrease of the NOS activity measured in vitro. Such
an irreversible blockage ex vivo has been already observed in the
rat brain at concentrations similar to that used in our study [44].
CsA with or without L-Arg increased NOS activity. Conversely,
the enzyme activity was reversed to the low values found in
controls in animals receiving both L-NNA and CsA (G3). When
L-Arg was given to the rats treated with CsA renal NOS activity
was significantly increased, while the assumption of L-Arg alone
did not modify the enzyme activity.
The in vitro increase of NOS activity elicited by CsA in the rat
kidney may appear in contrast with the decrease of GFR and
ERPF and the increase of protein excretion, which suggest that
CsA evokes a renal vasoconstriction. L-Arg given in association
with CsA reversed the hemodynamic conditions to baseline with
normalization of GFR, ERPF, serum creatinine levels and urinary
protein excretion. However, NOS activity in these rats was similar
to that measured in the rats treated with CsA alone.
It is conceivable that, acting via a complex with cyclophilin, CsA
causes an inhibition of the activity of the Ca/calmodulin-
dependent cNOS in the kidney [5]; after a prolonged exposure, in
the kidney such an effect could be counteracted by an increase of
iNOS activity. Such an effect may render critical the availibility of
L-Arg for NO synthesis: in the absence of an adequate substrate
supply, the increase of NOS activity would not correspond to a
parallelely increased production of NO. It has been already
reported in endothelium that intracellular L-Arg concentration is
sufficient for basal NO production, but is not enough to support
the increased NOS activity following stimulation with cytokines,
as during septic shock [45]. In the absence of L-Arg, NOS reduces
02 to H2O2 [46] or 02 [47]. It is possible that CsA-evoked NOS
hyperactivity is responsible of an oxidative stress, which could
partly account for both acute and chronic nephrotoxic effects of
the drug; L-Arg administration would prevent these side effects by
shifting NOS from a oxygen reductase to its physiological activity.
The Northern blot analysis of cNOS and iNOS transcripts in
renal tissues showed no significant difference in the six experi-
mental groups. This finding is not suprising to us, considering a
recent report in which some cytokines, such as IFN-y, TNF-a and
IL-I /3 were able to increase the NOS activity in human umbilical
vein endothelial cells in vitro by an up-regulation of tethrahydro-
biopterin synthesis without a parallel increase of NOS mRNA
[48].
In conclusion, we demonstrate a protective effect of L-Arg on
the nephrotoxicity induced by chronic administration of CsA at
high doses in the rat.
A positive effect of L-Arg on intrarenal hemodynamics
(SNGFR and SNRF) has been recently reported in an experimen-
tal model of short-term CsA administration in rats [49]. L-Arg was
found to restore the glomerular and tubular response to glycine
infusion after CsA treatment. Since glycine infusion causes renal
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vasodilation mediated by NO, CsA was supposed to diminish the
NO activity within the kidney which could be reversed by L-Arg
feeding. In that study no methodological approach was done to
measure NOS activity or mRNA encoding for NOS or cGMP as
second mediator. We tried to give further insight on the mecha-
nism governing not only the intrarenal hemodynamics but partic-
ularly the renal function consequences of CsA toxicity, including
proteinuria and creatinine increase. Even though L-Arg has a
clear beneficial effect on functional CsA nephrotoxicity, our data
failed to give direct and unequivocal evidence that NO is the only
mediator. Since the L-Arg-mediated decrease of proteinuria and
creatinine was completely reversed by L-NNA inhibition, we
suggest that NO may play a crucial role in L-Arg effect. We
suggest that CsA treatment increases NOS activity in the kidney,
by a mechanism which does not require a de novo synthesis of the
enzyme. Such an increase, which may counterbalance the vaso-
constrictive effects of the drug, is uneffective to reduce the toxic
effect of CsA in the absence of exogenous L-Arg. Administration
of L-Arg is likely to reduce CsA nephrotoxicity by accomplishing
the higher request of activated NOS for its substrate, thus
potentiating NO synthesis in the kidney. However, our data do not
exclude that L-Arg might protect the kidney against CsA effects
via other metabolic pathways.
Such effects occur not only by abolishing preglomerular vaso-
constriction induced by CsA with drop in GFR and ERPF, but
also by protecting from the consequent increase of filtration
fraction and urinary protein excretion. Therefore L-Arg not only
proved to be effective in abolishing the hemodynamic effects
exerted by CsA but was able to also re-establish the glomerular
permselectivity, the loss of which condition the evolution of the
glomerular damage toward sclerosis in several experimental mod-
els.
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